| pubmed-article:6721991 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6721991 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
| pubmed-article:6721991 | lifeskim:mentions | umls-concept:C0042523 | lld:lifeskim |
| pubmed-article:6721991 | lifeskim:mentions | umls-concept:C0013125 | lld:lifeskim |
| pubmed-article:6721991 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:6721991 | pubmed:dateCreated | 1984-7-9 | lld:pubmed |
| pubmed-article:6721991 | pubmed:abstractText | The pharmacokinetics of (+)-, (-)-, and (+/-)-verapamil were studied in five healthy volunteers following i.v. administration of the drugs. Pronounced differences of the various pharmacokinetic parameters were observed between the (-)- and (+)-isomers. The values for CL, V, Vz, and Vss of the (-)-isomer were substantially higher as compared to the (+)-isomer, whereas terminal t 1/ 2Z was nearly identical for both isomers. No dose dependency of the pharmacokinetics could be observed in two subjects who received 5, 7.5 and 10 mg of (-)- and 5, 25 and 50 mg of (+)-verapamil. Protein binding for the two isomers was also different. The fu of (-)- (0.11) was almost twice as much as that of (+)-verapamil (0.064). Pharmacokinetic parameters of (+/-)-verapamil, which was administered to three subjects who had received (+)- and (-)-verapamil, were very similar to the averaged values of the isomers given separately. Due to the higher CL of (-)-verapamil the extraction ratio of the (-)-isomer is substantially higher. Thus, it can be anticipated that following oral administration of racemic verapamil bioavailability of (-)-verapamil will be substantially less. Since the (-)-isomer is more potent than the (+)-isomer, the present findings could explain the reported differences in the concentration-effect relationship after i.v. and oral administration of racemic verapamil. | lld:pubmed |
| pubmed-article:6721991 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6721991 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6721991 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6721991 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6721991 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6721991 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6721991 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6721991 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6721991 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6721991 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6721991 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6721991 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6721991 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6721991 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6721991 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6721991 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6721991 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6721991 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6721991 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6721991 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6721991 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6721991 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6721991 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6721991 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6721991 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6721991 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6721991 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:6721991 | pubmed:issn | 0306-5251 | lld:pubmed |
| pubmed-article:6721991 | pubmed:author | pubmed-author:EichelbaumMM | lld:pubmed |
| pubmed-article:6721991 | pubmed:author | pubmed-author:MikusGG | lld:pubmed |
| pubmed-article:6721991 | pubmed:author | pubmed-author:VogelgesangBB | lld:pubmed |
| pubmed-article:6721991 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6721991 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:6721991 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6721991 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6721991 | pubmed:pagination | 453-8 | lld:pubmed |
| pubmed-article:6721991 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:6721991 | pubmed:meshHeading | pubmed-meshheading:6721991-... | lld:pubmed |
| pubmed-article:6721991 | pubmed:meshHeading | pubmed-meshheading:6721991-... | lld:pubmed |
| pubmed-article:6721991 | pubmed:meshHeading | pubmed-meshheading:6721991-... | lld:pubmed |
| pubmed-article:6721991 | pubmed:meshHeading | pubmed-meshheading:6721991-... | lld:pubmed |
| pubmed-article:6721991 | pubmed:meshHeading | pubmed-meshheading:6721991-... | lld:pubmed |
| pubmed-article:6721991 | pubmed:meshHeading | pubmed-meshheading:6721991-... | lld:pubmed |
| pubmed-article:6721991 | pubmed:meshHeading | pubmed-meshheading:6721991-... | lld:pubmed |
| pubmed-article:6721991 | pubmed:meshHeading | pubmed-meshheading:6721991-... | lld:pubmed |
| pubmed-article:6721991 | pubmed:meshHeading | pubmed-meshheading:6721991-... | lld:pubmed |
| pubmed-article:6721991 | pubmed:meshHeading | pubmed-meshheading:6721991-... | lld:pubmed |
| pubmed-article:6721991 | pubmed:meshHeading | pubmed-meshheading:6721991-... | lld:pubmed |
| pubmed-article:6721991 | pubmed:meshHeading | pubmed-meshheading:6721991-... | lld:pubmed |
| pubmed-article:6721991 | pubmed:year | 1984 | lld:pubmed |
| pubmed-article:6721991 | pubmed:articleTitle | Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration. | lld:pubmed |
| pubmed-article:6721991 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6721991 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6721991 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6721991 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6721991 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6721991 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6721991 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6721991 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6721991 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6721991 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6721991 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6721991 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6721991 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6721991 | lld:pubmed |
